 - Has received prior therapy with an immune checkpoint inhibitor e.g., anti-programmed cell death PD-1, anti-PD ligand 1 L1, anti-PD-L2 agent, or anti-cytotoxic T-lymphocyte-associated protein 4 CTLA-4 agent, etc. 